

SEC Number : CS201421675  
File Number : \_\_\_\_\_

**ALLIED CARE EXPERTS (ACE) MEDICAL  
CENTER-CEBU INC.**

\_\_\_\_\_  
(Company's Full Name)

982 N. Bacalso Avenue, Basak Pardo, Cebu City 6000

\_\_\_\_\_  
(Company's Address)

**008-899-890-000**

\_\_\_\_\_  
(TIN Number)

**032-383-3454**

\_\_\_\_\_  
(Telephone Number)

-

\_\_\_\_\_  
(Fax Number)

**SEC FORM 20-IS  
DEFINITIVE INFORMATION STATEMENT**

\_\_\_\_\_  
Form Type

Each Active Secondary License Type and File Name: NONE



982 N. Bacalso Avenue, Barangay Basak Pardo, Cebu City Philippines  
[www.acemccebu.com](http://www.acemccebu.com) / (032)383 - 3454

## **NOTICE OF ANNUAL STOCKHOLDERS' MEETING**

DEAR STOCKHOLDERS:

Please be informed that the Annual Stockholders' Meeting of Allied Care Experts (ACE) Medical Center-Cebu Inc. ("ACE-Cebu") will be held on August 20, 2020 (Thursday) at 8:00 o'clock in the morning, via Zoom Webinar, in light of the COVID pandemic.

For the conduct of the Webinar, please register on or before August 18, 2020, through the following

link: [https://zoom.us/webinar/register/WN\\_Xk9OZjnkRjqfixhGwT8Thg](https://zoom.us/webinar/register/WN_Xk9OZjnkRjqfixhGwT8Thg)

Once you have successfully registered, you will receive a confirmation email containing information about the webinar meeting.

The link will provide you the process for the registration. You will receive a confirmation email once you have successfully registered in the platform, including the details and procedures in the conduct of the meeting. Voting will be done via the online tool which you can access once you have logged in to the Webinar; voting in the election of directors may also be done *in absentia* through the above link.

The meeting shall be recorded (visual and audio) for future reference.

The Agenda:

- I. Call to Order
- II. Invocation
- III. Determination of Quorum
- IV. Welcome Message from the Chairman of the Board
- V. Reading and Approval of the Minutes of the Y2019 Annual Stockholders' Meeting
- VI. Audited Financial Report 2019
- VII. President's Report
- VIII. Ratification of the Acts and Proceedings of the Board of Directors, Officers, and Management of the Corporation
- IX. Election of the Board of Directors 2020-2021


- X. Appointment of External Auditor for the year 2020
- XI. Other Matters
- XII. Adjournment

Only stockholders of record at the close of business on July 31, 2020, Friday shall be entitled to notice of and to vote at the meeting. If you cannot personally attend the meeting, you may opt to send your proxy to attend in your behalf. Kindly submit your duly executed proxy form with the undersigned, via email, at [office.staff@acemccebu.com](mailto:office.staff@acemccebu.com) not later than 5:00 p.m. on August 19, 2020, but preferably, on August 18, 2020, to enable your proxy to register in the Zoom Webinar. Attached is a sample proxy form for your reference. [NOTE: Management is not soliciting proxies.]

The Information Statement and Management Report and SEC Form 17-A are available at the Corporation's website at [www.acemccebu.com](http://www.acemccebu.com).

You may contact the undersigned via email [office.staff@acemccebu.com](mailto:office.staff@acemccebu.com) or at telephone number: 032- 3833454 if you have inquiries/concerns regarding the meeting.

Very truly yours,

  
MARIETTA T. SAMOY  
Asst. Corporate Secretary

## PROXY

The undersigned, being a stockholder of Allied Care Experts (ACE) Medical Center-Cebu Inc. (the "Stockholder"), do hereby appoint and empower \_\_\_\_\_, as proxy to act and vote in the Stockholder's name and stead, at the Annual Stockholders' Meeting of Allied Care Experts(ACE) Medical Center-Cebu Inc., to be held on August 20, 2020.

IN WITNESS WHEREOF, I have hereunto set my hand this \_\_\_\_\_ day of \_\_\_\_\_, 2020.

\_\_\_\_\_  
(Signature over Printed Name of Stockholder)

**SECURITIES AND EXCHANGE COMMISSION  
SEC FORM 20-1S  
INFORMATION STATEMENT PURSUANT TO SECTION 20  
OF THE SECURITIES REGULATION CODE**

1. Check the appropriate box:

- ☐ Preliminary Information Statement  
☒ Definitive Information Statement

2. Name of Registrant as specified in its charter: **ALLIED CARE EXPERTS (ACE) MEDICAL CENTER-CEBU INC.**

3. Province, country or other jurisdiction of incorporation or organization: **Philippines**

4. SEC Identification Number: CS201421675

5. BIR Tax Identification Code: 008-899-890-000

6. Address of Principal Office: Postal Code:

982 N. Bacalso Avenue, Brgy Basak, Pardo, Cebu City 6000

7. Registrant's telephone number, including area code: (032) 3833454

8. Date, time and place of the meeting of security holders:

Date : **August 20, 2020**  
Time : **8:00 a. m.**  
Place : **Via Zoom Webinar**

9. Approximate date on which the Information Statement is first to be sent or given to security holders:

**July 29, 2020**

10. In case of Proxy Solicitations: NOT APPLICABLE

Name of Person Filing the Solicitation Statement:

Address and Tel. No. :

11. Securities registered pursuant to Section 8 and 12 of the Code or Section 4 and 8 of the RSA

Title of Each Class	Number of Shares of Common Stock
Outstanding	
Founder's Shares :	600
Common Shares :	169,957
Treasury Shares :	63

12. Are any or all registrant's securities listed in a Stock Exchange?

Yes                                 No        x

**PART I**

**INFORMATION REQUIRED IN INFORMATION STATEMENT**

**A. GENERAL INFORMATION**

**Date, time and place of meeting of security holders.**

**(a)** The stockholders' meeting shall be held on:

Date : **August 20, 2020**  
Time : **8:00 a. m.**  
Place : **Via Zoom Webinar**

Complete Mailing Address of Principal Office of Registrant:

982 N. Bacalso Avenue, Brgy Basak Pardo, Cebu City 6000

**(b)** The approximate date on which the information statement is first to be sent and given to security holders shall be **July 29, 2020**.

**Dissenter's Right of Appraisal**

There are no matters or proposed corporate actions included in the Agenda of the meeting which may give rise to a possible exercise by security holders of their appraisal right. Generally however, under Title X of the Revised Corporation Code of the Philippines, the stockholders of the Corporation have the right of appraisal provided that the procedures and the requirements of Title X governing the exercise of the right is complied with and/or followed

**Interest of Certain Persons in or Opposition to Matters to be Acted Upon**

No director, officer or nominee for election as director of the Company, or associate of a director, officer, or nominee for election as director has any substantial interest in any matter to be acted upon, other than election to office. No director has informed the Company in writing that he intends to oppose any action to be taken by the Company at the meeting.

**B. CONTROL AND COMPENSATION INFORMATION**

**Voting Securities and Principal Holders Thereof**

**(a)** Class of Voting Shares as of **June 30, 2020**:

	Shares Outstanding	No. of Vote Each Share Is Entitled
<b>Common Shares:</b>		
<b>Filipino</b>	<b>170,467</b>	<b>170,467</b>
<b>Foreign</b>	<b>90</b>	<b>90</b>
<b>Total</b>	<b>170,557</b>	<b>170,557</b>

(b) Record Date:

All stockholders of record as of **July 31, 2020** are entitled to notice of and to vote at the Annual Stockholders' Meeting.

(c) Manner of voting:

The holders of common stock are entitled to one vote per share, but in connection with the cumulative voting feature applicable to the election of directors, each stockholder is entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. A stockholder may cast all of such votes for a single nominee or may apportion such votes among any two or more nominees. The shares shall be voted/cast by secret balloting and/or raising of hands. In all matters included in the agenda, except the election of directors, the counting of votes will be done through the regular method.

(d) Security Ownership of Certain Record and Beneficial Owners and Management

(1) Security Ownership of Certain Record and Beneficial Owners (of more than 5%) as of June 30, 2020

The persons known to the registrant to be directly or indirectly the record or beneficial owner of more than 5% of the registrant's voting securities as of June 30, 2020, are as follows:

<b>Title of Class</b>	<i>Name, Address of record owner and Relationship with Issuer</i>	<b>Name of Beneficial Owner and Relationship with Record Owner</b>	<b>Citizenship</b>	<b>No. of Shares Held</b>	<b>Percent</b>
Common Founder	Marilyn R. Enriquez	Amado Manuel C. Enriquez, Jr. / Husband, Father	Filipino	Founder — 90 Common — 22410 Total — 22500	13.19%
Common Founder	Michael Edward R. Enriquez				
Common Founder	Miguel Antonio R. Enriquez				
Common Founder	Edna R. Molon	Nicolas S. Molon / Husband, Father, Brother-in-Law	Filipino	Founder — 50 Common — 12,450 Total — 12500	7.32%
Common Founder	Jan Noel R. Molon				
Common Founder	Myla Noreen R. Molon				
Common Founder	Flordelis M. Nasol				



(2) Security Ownership of Directors and Management as of June 30, 2020:

(1) Title of Class	(2) Name of Beneficial Owner	Position	(3) Amount and Nature of Beneficial Ownership	(4) Citizenship	(5) Percentage (%) of Class
	<b>Board of Directors:</b>				
Common Founder	Amado Manuel C. Enriquez, Jr.	Director	Direct – 15,000 Founder – 60  Common – 14,940  Indirect – 7,500  Founder – 30  Common – 7,470	Filipino	13.19%
Common Founder	Geanie Cerna- Lopez	Director	Direct – 2,500 Founder – 10 Common – 2,490  Indirect – 2,500 Founder – 10 Common – 2,490	Filipino	2.93%
Common Founder	Luisito R. Co	Director	Direct – 2,500  Founder – 10 Common – 2,490	Filipino	1.46%
Common Founder	Roland Mark M. Gigataras	Director	Direct – 2,500  Founder – 10 Common – 2,490	Filipino	1.46%
Common Founder	Velma T. Chan	Director	Direct – 5,006  Founder – 20 Common – 4,986	Filipino	2.93%
Common Founder	Julio L. Gonzalez	Director	Direct – 2,500  Founder – 10  Common - 2,490	Filipino	1.46%
Common Founder	Wyben R. Briones	Director	Direct – 2,000 Founder -10	Filipino	1.46%

			Common- 1,990 Indirect – 500 Common - 500		
Common Founder	Floram C. Limotlimot	Director	Direct – 2,500 Founder – 10 Common – 2,490 Indirect – 2,500 Founder – 10 Common – 2,490	Filipino	2.93%
Common Founder	Joy C. Luna	Director	Direct – 2,500 Founder – 10 Common – 2,490 Indirect – 5,000 Founder – 20 Common – 4,980	Filipino	4.40%
Common Founder	Nicolas S. Molon	Director	Direct – 2,500 Founder – 10 Common – 2,490 Indirect - 10,000 Founder – 40 Common- 9,960	Filipino	7.32%
Common Founder	Roberto M. De Leon	Director	Direct – 2,500 Founder – 10 Common – 2,490 Indirect – 2,500 Founder – 10 Common – 2,490	Filipino	2.93%
Common Founder	Felix P. Nolasco	Director	Direct – 2,500 Founder – 10 Common – 2,490 Indirect – 2,500 Founder – 10 Common -	Filipino	2.93%

			2,490		
Common Founder	Evangeline Y. Zozobrado	Director	Direct – 2,500 Founder – 10 Common – 2,490 Indirect – 5,000 Founder – 20 Common- 4,980	Filipino	4.40%
Common Founder	Neonita C. Antigua	Director	Direct – 1,200 Founder – 10 Common- 1,190 Indirect – 1,300 Common- 1,300	Filipino	1.46%
Common Founder	John M. Mata	Director	Direct – 2,500 Founder – 10 Common – 2,490	Filipino	1.46%
<b>Total for Directors</b>			<b>90,006</b>		<b>52.77%</b>

<b>Executive Officers:</b>					
Common Founder	Cerna-Lopez, Geanie	President	Direct – 2,500 Founder – 10 Common – 2,490 Indirect – 2,500 Founder – 10 Common – 2,490	Filipino	2.93%
Common Founder	Luisito R. Co	Vice President	Direct – 2,500 Founder – 10 Common – 2,490	Filipino	1.46%
Common Founder	Floram C. Limotlimot	Treasurer	Direct – 2,500 Founder – 10 Common – 2,490 Indirect – 2,500 Founder – 10 Common – 2,490	Filipino	2.93%
Common Founder	Velma T. Chan	Secretary	Direct – 5,006 Founder – 20 Common – 4,986	Filipino	2.93%
<b>Total for Officers</b>			<b>17,506</b>		<b>10.26%</b>
	<b>Directors and Exec. Officers as a Group</b>		<b>90,006</b>		<b>52.77%</b>

- (3) There are no voting trust holders of 5% or more.
- (4) The Company is not aware of any voting trust agreement/s or similar agreement/s which may result in a change in control of the Company.
- (5) The company is a party to the following legal proceedings:

**Civil Case No. R-CEB-18-00601-CV, Branch XI, Cebu City**

**(Complaint for Issuance of Certificate of Stock, Declaration of Sale in Installment as Subscription Contract, Declaration of Rights or Pre-Emption, and for Attorney's Fees) – Ferdinand Kionisala vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. De Leon, Amado Manuel C. Enriquez Jr., Floram C. Limotlimot, Roland Mark M. Gigataras, Joy A. Luna, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald L. Ramiro, Marietta T.**

Samoy and Evangeline Y. Zozobrado.

Status: Plaintiff filed a Motion for Partial Summary Judgment on May 2, 2018; respondents filed their Opposition to the Motion on May 15, 2018; the motion is still pending resolution by the presiding judge of branch XI, RTC Cebu

**Civil Case No. R-CEB-18-01248-CV, Branch XI, Cebu City**

**(Declaration of Sale in Installment as Subscription Contract, Declaration of Rights of Pre-Emption, and Attorney's Fees)** - Dax Matthew M. Quijano, Rose Marie P. Quijano, Eric Y. Cheung, Girlie Cheung and Candice Joy A. Sia vs. Geanie Cerna- Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. de Leon, Amado Manuel C. Enriquez, Jr., Floram C. Limotlimot, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald L. Ramiro, Marietta T. Samoy and Evangeline Y. Zozobrado.

Status: The defendants based in Cebu have already filed their Answer to the Complaint. However, the complaint for Manila-based doctors are yet to be served. Awaiting notice of pre-trial from the court.

**Special Civil Action Case No. R-CEB-18-08795-SC, Branch XI, Cebu City**

**(For Mandamus to Issue 100% Pre-Emptive Rights, Damages and for Attorney's Fees) - Leo T. Sumatra, Sps. Stephen Paul M. Bergado and Conchita B. Bergado, Marie Davielene Beatriz Ong-Dy and Leonard Matthew Dy, et al vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez and Velma T. Chan**

Status: Respondents filed their Comment to the Petition last January 7, 2019; the Plaintiffs have filed their reply. Last February 2020, the case was heard for possible arbitration. The defendants offered to buy back the shares of the complainants at a higher price.

Subsequent hearing has been deferred because of the Covid crisis.

FOR DETAILED DESCRIPTION OF THE CASES, PLEASE REFER TP PAGES 17-20 OF THE PROSPECTUS IN THE WEBSITE.

- (e) No change in control of the registrant has occurred since the beginning of its last fiscal year.

## **Directors and Executive Officers**

### **(a) Directors/Nominees and Executive Officers**

There are fifteen (15) members of the Board, two (2) of whom are independent directors. The term of office of each member is one (1) year; to hold office until the next succeeding annual stockholders' meeting and until his/her successor is elected and qualified.

The following are the current members of the Board of Directors:

1. Enriquez, Amado Manuel Jr. C.
2. Lopez, Geanie Cerna
3. Gigataras, Roland Mark M.
4. Co, Luisito R.
5. Chan, Velma T.
6. Gonzalez, Julio L.
7. Briones, Wyben R.
8. Limotlimot, Floram C.
9. Luna, Joy C.
10. Nolasco, Felix P.
11. De Leon, Roberto M.
12. Molon, Nicolas S.
13. Zozobrado, Evangeline Y.
14. Antigua, Neonita C. (Independent Director)
15. Mata, John M. (Independent Director)

### **Nominees for Election as Members of the Board of Directors**

The following have been nominated to the Board for the ensuing year:

1. Briones, Wyben R.
2. Cerna Lopez, Geanie
3. Chan, Velma T.
4. Cimafranca, Jude Martin F.
5. De Castro, Felicisimo (Independent Director)
6. Dela rosa, Esmeralda (Independent Director)
7. Enriquez, Amado Manuel Jr. C.
8. Enriquez, Miguel Antonio R.
9. Gabriel, Enjel A.
10. Gigataras, Roland Mark M.
11. Molon, Nicolas
12. Ramiro, Ronald (Independent Director)
13. Salonga, McArthur Conrado Jr. A.
14. Samoy, Marietta T.
15. Zozobrado, Evangeline Y.

[Please refer to Annex “A” (pages 24-29) for the summary of the qualifications of the current Directors/Nominees and Executive Officers]



The Company has complied with the guidelines on the nomination and election of independent directors as set forth in Rule 38 of the Amended Implementing Rules and Regulations of the Securities Regulation Code. The nominated independent directors are as follows: Dr. Esmeralda dela Rosa, Dr. Felicisimo de Castro and Dr. Ronald Ramiro, and were nominated by Dr. Evangeline Zozobrado, Dr. Amado Enriquez and Dr. Esmeralda dela Rosa, respectively. The nominees are not related to their respective nominating stockholder and were pre-screened by the Nominations Committee composed of Dr. Luisito R. Co, Ms. Joy C. Luna, Ms. Neonita C. Antigua, Dr. Florentina U. Ty and Dr. John M. Mata.

The Company's key executive officers as of June 30, 2020 are as follows:

Geanie Cerna-Lopez	- President
Floram C. Limotlimot	- Treasurer
Velma T. Chan	- Corporate Secretary

The Officers (per the Company's By-Laws) are elected/appointed annually by the Board of Directors during its organizational meeting following the annual stockholders' meeting, each to hold office for one (1) year until the next organizational meeting of the Board in the following year or until a successor shall have been elected/appointed and shall have qualified.

[Please refer to attached Annex "A" (pages 24 to 29) for the summary of qualifications of the current Executive Officers]

### ***(3) Significant Employees***

The Company relies significantly on the continued collective efforts of its senior executive officers and expects each employee to do his share in achieving the Company's goals.

### ***(4) Family Relationships***

Except for Ms. Floram Limotlimot (Corporate Treasurer) and Ms. Joy Luna (Director) and Dr. Amado Manuel C. Enriquez, Jr. (Chairman) and Dr. Miguel Antonio R. Enriquez (Nominee), there are no other family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, persons nominated or chosen by the Company to become directors, or executive officers, any security holder of certain record, beneficial owner or management.

### **Involvement in Certain Legal Proceedings**

The following directors are parties to legal proceedings in their capacity as directors of the Company:

1. Geanie Cerna-Lopez

2. Velma T. Chan
3. Luisito R. Co
4. Roberto M. De Leon
5. Amado Manuel C. Enriquez, Jr.
6. Floram C. Limotlimot
7. Roland Mark Gigataras
8. Joy C. Luna
9. Nicolas S. Molon
10. Felix P. Nolasco
11. Evangeline Y. Zozobrado

**Civil Case No. R-CEB-18-00601-CV, Branch XI, Cebu City**

**(Complaint for Issuance of Certificate of Stock, Declaration of Sale in Installment as Subscription Contract, Declaration of Rights or Pre-Emption, and for Attorney's Fees)** – Ferdinand Kionisala vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. De Leon, Amado Manuel C. Enriquez Jr., Floram C. Limotlimot, Roland Mark M. Gigataras, Joy C. Luna, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald L. Ramiro, Marietta T. Samoy and Evangeline Y. Zozobrado.

Status: Plaintiff filed a Motion for Partial Summary Judgment on May 2, 2018; respondents filed their Opposition to the Motion on May 15, 2018; the motion is still pending resolution in court at branch RTC XI of Cebu City.

**Civil Case No. R-CEB-18-01248-CV, Branch XI, Cebu City**

**(Declaration of Sale in Installment as Subscription Contract, Declaration of Rights of Pre-Emption, and Attorney's Fees)** - Dax Matthew M. Quijano, Rose Marie P. Quijano, Eric Y. Cheung, Girlie Cheung and Candice Joy A. Sia vs. Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. de Leon, Amado Manuel C. Enriquez, Jr., Floram C. Limotlimot, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald L. Ramiro, Marietta T. Samoy and Evangeline Y. Zozobrado.

Status: Respondents ACE, Velma Chan, Luisito Co, Floram Limotlimot and Mark Gigataras have filed their Answer to the Complaint. No summons were issued against the other respondents who are based in Manila. Still awaiting for pre-trial.

**Special Civil Action Case No. R-CEB-18-08795-SC, Branch XI, Cebu City**

**(For Mandamus to Issue 100% Pre-Emptive Rights, Damages and for Attorney's Fees)** - Leo T. Sumatra, Sps. Stephen Paul M. Bergado and Conchita B. Bergado, Marie Davielene Beatriz Ong-Dy and Leonard Matthew Dy, et al vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez and Velma T. Chan

Status: Respondents filed their Comment to the Petition last January 7, 2019; the Plaintiffs have filed their reply. Last February 2020, the case was heard at an Arbitration Court and the respondents offered to buy back the shares of the complainants at a higher cost. Subsequent hearing has been deferred because of the Covid crisis.

As of 30 June 2020, to the knowledge and/or information of the Company, except for the abovementioned Directors, none of the Company's other Directors or Executive Officers have been involved in any legal proceedings during the last five (5) years that are material to an evaluation of their ability or integrity to act as such.

No director has resigned or declined to stand for re-election to the board of directors since the date of the last annual meeting of security holders due to disagreement with the registrant on any matter relating to the registrant's operations, policies and practices.

***(5) Certain Relationships and Related Transactions***

(1) Except for Ms. Floram Limotlimot (Corporate Treasurer) and Ms. Joy Luna (Director) and Dr. Amado Manuel C. Enriquez, Jr. (Chairman) and Dr. Miguel Antonio R. Enriquez (Nominee), there are no other family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, persons nominated or chosen by the Company to become directors, or executive officers, any security holder of certain record, beneficial owner or management.

(2) Aside from the party mentioned above, there is no other relationship that has existing negotiations on material transactions.

(3) In 2019, the outstanding advances from its founders in the amount of PHP 9,503,555.00 as reflected in the 2018 Annual Financial Statement was paid off without interest by the Company.

(3) There is no transaction with promoters for the past 5 years.

**(b) Compensation of Directors and Executive Officers**

**SUMMARY COMPENSATION TABLE**

(a)	(b)	(c)	(d)	(e)
Name & Principal Position	Year	Salary	Bonus	Other Compensation **
A. Dr. Geanie Cerna-Lopez President		-	-	-
B. Dr. Luisito Co Vice President		-	-	-
C. Ms. Floram Limotlimot Treasurer		-	-	2,200,000
D. Dr. Velma Chan Corporate Secretary		-	-	2,200,000
E. Aggregate For The Above Named CEO & Officers	2020- Estim.	-	-	-
	2019	-	-	-
	2018*	-	-	-
F. Aggregate For The Officers And Directors As A Group	2020- Estim.	-	-	-
	2019	-	-	-
	2018*	-	-	-

*\* refers to a previous set of Officers*

*\*\* This **pertains** to the exemplary services rendered by the two directors to the corporation since 2014, which **involve** the set up and management of documents and documentary processing of all requirements for the SEC secondary license and the subsequent regulatory reports.*

- a. Except for per diem (PHP 10,000.00/board meeting) for each director during board meetings, there are no bonus, profit sharing or other compensation plan, contract or arrangement in which any director, nominee for election as director, or executive officers of the registrant will participate.
- b. The Company has no registered, non-contributory retirement plan.
- c. The Company has no existing options, warrants or rights to purchase any securities

**(c) Independent Public Accountants**

The Company's external auditor is the auditing firm of Minerva and Company, CPAs. For the year 2020, the Board will recommend the auditing firm based on the recommendation of the Audit Committee composed of Chairperson Mrs. Neonita C. Antigua, and the following members: Dr. Conrado Mc Arthur A. Salonga, Jr., Dr. Marietta T. Samoy, Dr. Michael Edward R. Enriquez, Dr. Roberto M. de Leon, and Dr.

Luisito R. Co, subject to stockholders' approval.

- b. The Audit committee evaluates proposals based on the quality of service, commitment for deadline and fees. The committee may require a presentation from each proponent to clarify some issues.
- c. Minerva and Company, CPAs, represented by its engagement partner, Mr. Elmer Minerva, is the external auditor of the Company for the most recently completed year 2019. They were engaged by the Company in 2018, succeeding the Company's external auditor for 2017, Aniceto M. Y and Associates. Pursuant to SRC Rule 68 (3) (b) (iv) of the Amended Implementing Rules and Regulations of the Securities Regulation Code (SRC) (re: rotation of external auditors), the Company has not engaged Mr. Elmer Minerva for more than five years.
- d. Representatives of Minerva and Company, CPAs are expected to be present during the stockholders' meeting. The representatives will have the opportunity to make statements if they desire to do so and will be available to respond to appropriate questions from the security holders.
- e. During the two (2) most recent fiscal years or any subsequent interim period, the independent auditor has not resigned nor was dismissed or has declined to stand for reappointment after the completion of the current audit.
- f. The aggregate annual external audit fees billed for each of the last two (2) fiscal years for the audit of the registrant's annual financial statements or services that are normally provided by the external auditor are as follows:  
For the year 2018 - P150,000 (billed and paid in 2019)  
For the year 2019 - P300,000 ( all paid in 2020)
- g. The above audit fees are inclusive of the following: (a) audit, other assurance and related services by the External Auditor that are reasonably related to the performance of the audit or review of the Company's financial statements (P300,000); and (b) All Other Fees, excluding out of pocket expenses reimbursed by the Company as of April 30, 2020 (P374,624.16).
- h. The company does not have any existing tax cases with the Bureau of Internal Revenue or any tribunal as of the reporting date.

## **C. OTHER MATTERS**

### **Action with Respect to Reports**

The approval of the stockholders on the following will be taken up:

Minutes of the April 14, 2019 Annual Stockholders' Meeting. The Minutes cover the following items:

- I. Reading and approval of the minutes of the 2018 annual stockholders' meeting
- II. Treasurer's report
- III. President's report
- IV. Election of directors
- V. Other matters
- VI. Adjournment

The approval or disapproval of the above Minutes will refer only to the correctness of the Minutes and will not constitute an approval/disapproval of the matters stated in the Minutes.

### **Other Proposed Actions**

1. Ratification of all corporate acts and resolutions during the past year of the Board, Officers and Management. These acts are covered by resolutions duly adopted in the usual course of business such as opening of bank accounts and designation of authorized signatories for various transactions, etc.
2. Election of Directors including Independent Directors for Y2020-2021
3. Appointment of External Auditor for fiscal year ending 31 December 2020

### **Amendment of Charter, By-Laws and other Documents**

There is no action to be taken with respect to the Company's charter, bylaws or other documents.

### **Voting Procedures**

Except on the election of directors, an affirmative vote by the stockholders owning at least a majority of the outstanding capital stock shall be sufficient to approve matters requiring stockholder's action. The holder of a majority interest of all outstanding stock of the Company entitled to vote at the meeting, in person or by proxy, shall constitute a quorum for the transaction of business. The holders of common stocks are entitled to one vote per share, but in connection with the cumulative voting feature applicable to the election of directors, each stockholder is entitled to as many votes as shall equal the number of shares held by such person at the close of business on the record date, multiplied by the number of directors to be elected. A stockholder may cast all of such votes for a single nominee or may apportion

such votes among any two or more nominees. The shares shall be voted/cast by secret balloting and/or raising of hands. Stockholders shall be entitled to vote either in person or by proxy.

*Method of Counting Votes*

The Committee on Elections, assisted by the Company's external auditor, will be responsible for counting the votes.

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this report is true, complete and correct. This report is signed in the City of Makati on **15 July 2020**.

**ALLIED CARE EXPERTS(ACE) MEDICAL CENTER-CEBU INC.**

By:

  
**MARIETTA T. SAMOY**  
*Assistant Corporate Secretary*

Upon the written request of the stockholder, the Company undertakes to furnish said stockholder a copy of SEC Form 17-A free of charge, except for exhibits attached thereto which shall be charged at cost. Any written request for a copy of SEC Form 17-A shall be addressed as follows:

***Allied Care Experts(ACE) Medical Center-Cebu Inc.  
982 N. Bacalso Avenue, Brgy Basak, Pardo,  
Cebu City 6000  
Attention: The Assistant Corporate Secretary***

**ANNEX “A”**

**BUSINESS PROFILE OF THE INCUMBENT BOARD OF DIRECTORS/OFFICERS/NOMINEES:**

Name	Business and Professional Work Experience
<p>Enriquez, Amado Manuel Jr. C.</p> <p>66 years old, Filipino</p>	<p>Chairman of the Board – Manila East Medical Center (2007-2008, 2017); Paranaque Doctors Hospital (2012-2017); ACE Medical Center Baypointe, Subic (2007-2011); Unihealth Paranaque Hospital (2014- 2017); Alaminos Medical Center Foundation (2001- present)</p> <p>Founding Chairman – ACE Medical Center Valenzuela, ACE Medical Center Baliwag, ACE Medical Center Pateros, ACE Medical Center Malolos, ACE Medical Center Mandaluyong, ACE Medical Center Palawan, ACE Medical Center Iloilo, ACE Medical Center Tacloban, ACE Medical Center Bohol, ACE Medical Center Dumaguete, ACE Medical Center Bacolod, ACE Medical Center General Santos, ACE Medical Center CDO, ACE Medical Center Dipolog, ACE Medical Center Zamboanga, ACE Medical Center Butuan</p> <p>Active consultant in Cardiovascular-Thoracic Surgery – St. Lukes Medical Center, Manila East Medical Center, ACE Medical Center Hospitals.</p>
<p>Gigataras, Roland Mark M.</p> <p>44 years old, Filipino</p>	<p>Director – ACE MC Cebu (2015-present)</p> <p>Vice-Chairman – ACE MC – Cebu (2015-present)</p> <p>Practicing Neurosurgeon at:</p> <p>Cebu Velez General Hospital</p> <p>Chong Hua Hospital (Fuente Osmena, Cebu) Chong Hua Hospital (Mandaue City, Cebu) Perpetual Succour Hospital</p> <p>Cebu Doctors’ University Hospital</p> <p>Cebu South General Hospital</p>



	Mendero Medical Center Cebu North General Hospital Seamen's Hospital University of Cebu Medical Center Gullas Memorial Hospital Visayas Community Medical Center Sacred Heart Hospital St. Vincent General Hospital Adventist Hospital Cebu City Medical Center Vicente Sotto Memorial Medical Center
Cerna-Lopez, Geanie C. 65 years old, Filipino	President - Las Pinas City Medical Center Medical Director- Unihealth Paranaque Management Consultant - Medical Center Muntinlupa Past President - Medical Center Muntinlupa (2016) Past Hospital Admin - UniHealth Paranaque Hospital (2016) and Las Pinas City Medical Center(2016) Past president Paranaque Doctors Hospital (2015)
Co, Luisito R. 51 years old, Filipino	Director – ACE MC Cebu (2014-present) Vice-President – ACE MC – Cebu (2014-present) Surgeon: Sacred Heart Hospital St. Vincent General Hospital Perpetual Succour Hospital Cebu South General Hospital Visayas Community Medical Center
Chan, Velma T. 53 years old, Filipino	Director – ACE MC- Cebu (2014-present) Assistant Corporate Secretary – ACE MC – Cebu (2014-2015) Corporate Secretary – ACE MC – Cebu (2016-present)

	<p>Pediatric Intensive Care Consultant:</p> <p>Chong Hua Hospital</p> <p>Cebu (Velez) General Hospital</p> <p>Visayas Community Medical Center</p> <p>Perpetual Succour Hospital</p> <p>Sacred Heart Hospital</p> <p>St. Vincent General Hospital</p>
<p>Gonzalez, Julio L.</p> <p>69 years old, Filipino</p>	<p>Director – ACE MC- Cebu (2017 -present)</p> <p>General Pediatrician at Chong Hua Hospital, Perpetual Succour Hospital, Visayas Community Medical Center, Cebu Puericulture Center and Maternity House, University of Cebu Medical Center</p>
<p>Limotlimot, Floram C.</p> <p>62 years old, Filipino</p>	<p>Director – ACE MC Cebu (2014-present)</p> <p>Assistant Treasurer – ACE MC – Cebu (2014-2015)</p> <p>Corporate Treasurer – ACE MC – Cebu (2016-present)</p> <p>Standard Chartered Bank 2008-2012 VP Visayas Philippine National Bank 2012- 2017 AVP Cebu Main BPI 1998-2008 Sr. Manager Far East Bank and Trust Co. 1974-1998</p> <p>SEC Certified Fixed Income Salesman &amp; Broker</p> <p>Insurance Commission Certified Insurance Agent</p> <p>Civil Service Eligibility</p>
<p>Luna, Joy C.</p> <p>52 years old, Filipino</p>	<p>Director – Manila East Medical Center (2005- present); Diliman Doctors Hospital (2015-present); Allied Care Experts Medical Center Cebu (2014-present); Pharmacy Director – Manila East Medical Center (MEMC) (2002-present); Head, Central Supplies Dept. – MEMC (2002-present); Head, Professional Dev't. and Training Dept. – MEMC (2014-present); Head, Pharmacy Dept. – Ace Medical Center Valenzuela (2014-present)</p>
<p>De Leon, Roberto M.</p> <p>67 years old, Filipino</p>	<p>Chairman – Unihealth-Baypointe Hospital &amp; Medical Center, Inc. (Subic Bay Freeport Zone) 2017 President – Unihealth-Valenzuela Hospital &amp; Medical Center (2017) Medical Director – YGEIA Medical Center Chairman, Dept. of Surgery – ACE</p>

	Medical Center Valenzuela; Uni-Health Paranaque Hospital and Medical Center (2017)
Zozobrado, Evangeline Y. 66 years old, Filipino	Pediatric Consultant - Asian Hospital and Medical Center (2002-present) Corp. Secretary - Medical Center Muntinlupa (2016- 2017), ACE Baliwag (2012-present) Medical Director - Las Pinas City Medical Center (2014-2016) Hospital Administrator – Diliman Doctors Hospital (2017) Pediatric Consultant - Paranaque Doctors Hospital, University of Perpetual Help System Dalta Hospital and Medical Center
Briones, Wyben R. 66 years old, Filipino	Doctor of Medicine. Specialty: Neurosurgery. Consultant: Cebu Velez General Hospital Chong Hua Hospital (Fuente Osmena, Cebu) Chong Hua Hospital (Mandaue City, Cebu) Perpetual Succour Hospital Cebu Doctors' University Hospital Visayas Community Medical Center Sacred Heart Hospital St. Vincent General Hospital University of Cebu (UC) Medical Center Mactan Doctors Hospital
Molon, Nicolas S. 73 years old, Filipino	Doctor of Medicine. Specialty – Anesthesiology.  Founding Chairman – ACE MC Cebu. Chairman: Calamba Doctors Hospital (1994 - present), MEMC (2002 – 2010), Marikina Valley Medical Center (2009 -2015), Diliman Doctors Hospital (2011-2016), BDMC (2010 - 2015), Medical Center Imus (2000 – 2009). President – Metrosouth Medical Center (1996 – 1999).
Nolasco, Felix P. 67 years old, Filipino	Doctor of Medicine. Specialty – ENT-Head and neck Surgery, Maxillofacial Trauma Surgery. Consultant – Asian Hospital and Medical Center, Manila Doctors Hospital. President, Baypoint Hospital and Medical Center, SBMA, 2013 to 2016. Medical Director, Unihealth Paranaque Hospital and Medical Center, 2014 to 2016. Administrator, Unihealth Paranaque Hospital and Medical Center, 2017 to present. Vice-Chairman, ACE Valenzuela, 2015; ACE Baliwag, 2015. Vice-President, ACE Medical Center – Bohol, 2016 – present.
Antigua, Neonita C.	Bachelor of Science, Major in Accountancy. Passed - Licensure Exam of Life and Non-life Insurance.

60 years old, Filipino	<p>Passed - Licensure Exam of Real Estate Broker. Former Vice-President Quota International – Mandaue Chapter. Treasurer – Royale Cebu Estates Homeowners Association.</p>
<p>Mata, John M. 52 years old, Filipino</p>	<p>Doctor of Medicine. Specialty – Urology. Consultant – Chong Hua Hospital, Perpetual Succor Hospital, Cebu Velez General hospital, Vicente Sotto Memorial Hospital, Miller Hospital, North General Hospital, Vicente Gullas Medical Center, Visayas Community Medical Center, Sacred Heart Hospital, UC Medical Center, in Cebu.</p>
<p>Dela Rosa, Esmeralda V.  64 years old, Filipino</p>	<p>Doctor of Medicine. Specialty – internal Medicine.</p> <p>Chairman of the Board - Las Pinas City Medical Center (LPCMC) President - ACE – Baliwag Treasurer – Medical Center Muntinlupa, Inc / LPCMC Hospital Administrator - LPCMC Corporate Secretary - LPCMC Medical Director - ACE – Valenzuela / PDH Chief of Clinics - MCMI / LPCMC/ Paranaque Doctors Hospital / Unihealth Paranaque Human Resource Director - MCMI / PDH / LPCMC Chief, Medical Service - MCMI Head, Internal Audit - MCMI Head, Nursing Service - UPAR / PDH</p>
<p>Ramiro, Ronaldo L.  63 years old, Filipino</p>	<p>Doctor of Medicine. Specialty – Surgery.</p> <p>PAST POSITIONS: Medical Director, Ramiro Community Hospital – 1990 to 2017 Chairman, Department of Surgery, Ramiro Community Hospital-1990 to 2017.</p> <p>PRESENT POSITIONS: President, Allied Care Experts (ACE) Medical Center – Bohol, Inc.- 2014 to present Hospital Administrator, Allied Care Experts (ACE) Medical Center – Bohol, Inc.- 2019 to present</p>
<p>Salonga, McArthur Conrado, Jr. A.  51 years old, Filipino</p>	<p>Doctor of Medicine. Specialty – General Surgery. Subspecialty - Advance Minimally Invasive Surgery / Endocrine and Bariatric Surgery Consultant: Cebu Doctors' University Hospital, North General Hospital, South General Hospital, St. Vincent General Hospital, Velez General Hospital, Perpetual Succour Hospital,</p>

	Mactan Doctors' Hospital, Mandaue General Hospital, Mendero General Hospital, Ormoc Sugar Planters Asso. Hospital.
De Castro, Felicisimo D.  65 years old, Filipino	Doctor of Medicine. Specialty – Ophthalmology. Consultant: ACE MC – Quezon City, ACE-Baypoint Medical Center, Unihealth Tagaytay Hospital and Medical Center.
Cimafranca, Jude Martin F.  52 years old, Filipino	Doctor of Medicine. Specialty – Anatomic and Clinical Pathology. Hospital Affiliations: Chong Hua Hospital, Cebu City. Visayas Community Medical Center, Cebu City. Gov. Celestino Gallares Memorial Hospital, Tagbilaran City. Tagbilaran Maternity and Puericulture Center, Tagbilaran City.
Gabriel, Enjel A.  56 years old, Filipino	Doctor of Medicine. Specialty – Internal Medicine. Subspecialty – Gastroenterology. Consultant: Chong Hua Hospital- Fuente, Chong Hua Hospital – Mandaue, Gullas Hospital, Perpetual Succour Hospital, Visayas Community Medical Center, Cebu Doctor's University Hospital, Cebu (Velez) General Hospital, St.Vincent's General Hospital, UC Medical Center, Vicente Sotto Memorial Medical Center.
Samoy, Marietta T.  63 years old, Filipino	Doctor of Medicine. Specialty – Obstetrics and Gynecology.  Muntinlupa Medical Center - Administrator, 2020-2021. Paranaque Doctors Hospital: Head - Department of Ob Gyne . Head - business office 2019 Las Pinas City Medical Center: Head - Pharmacy. 2019 Diliman Doctors Hospital: Board Member, 2018-2019.
Enriquez, Miguel Antonio R.  31 years old, Filipino	Dentist.  Hospital Administrator- Allied Care Experts (ACE) Medical Center- Valenzuela Vice President-Allied Care Experts (ACE) Medical Center Quezon City Vice President-Allied Care Experts (ACE) Medical Center Pateros.

## **ANNEX “B”**

### **MANAGEMENT REPORT**

#### **A. INDEPENDENT ACCOUNTANT**

During the two most recent fiscal years or any subsequent interim period, the Company’s independent accountant, Minerva and Co. CPAs has not resigned, nor was dismissed or otherwise ceased performing services for the Company; there were no disagreements with the said independent accountant on any matter of accounting and financial disclosure.

#### **B. Description of Business**

Allied Care Experts (ACE) Medical Center – Cebu, Inc. (herein referred to as the “Company”) was organized and incorporated under the Philippine laws and registered with the Securities and Exchange Commission on November 7, 2014 under SEC Registration No. CS201421675. The Company’s primary purpose is to establish, maintain, operate, own and manage hospitals, medical and related healthcare facilities and business such as but without restriction to clinical laboratories, diagnostic centers, ambulatory clinic, condo-hospital, scientific research institutions and services which shall provide medical, surgical, nursing, therapeutic, paramedic or similar care, provided that purely professional, medical or surgical services shall be performed by duly qualified and licenses physicians or surgeons who may or who may not be connected with the hospitals and whose services shall be freely and individually contracted by the patients.

The principal office address of the Company is located 982 N. Bacalso Avenue, Basak Pardo, Cebu City. The Company has yet to start its commercial operations and is now on the final stage of its construction of the medical facility (hospital). The hospital building includes leasable clinical facilities for medical and dental practitioners, who are shareholders of the Company.

The Company’s secondary license to sell its common shares to the public pursuant to Section 12 of the Securities Regulation Code (SRC) was approved on December 27, 2018.

ACE Medical Center - Cebu will set up a tertiary health care facility with an organized, systematic, cost-effective, sympathetic, and holistic approach to its goal in providing the best quality and justifiable medical services to its clients and stakeholders. ACE Medical Center - Cebu will be an 8-storey 176-bed capacity hospital with 3 basement parking and a helipad, with total floor area of 25,325 sq.m. constructed in a 3,948 sq.m. property located in the center of South Cebu City, along N. Bacalso Avenue, Barangay Basak,Pardo. It will be a multidisciplinary specialty medical facility that will house medical specialists who are subscribers to the capital stock of the

Corporation.

The Company's target date of commencement of its business operations is on the last quarter of 2020. Its medical facility is now on its final stage of installation of medical equipment. The hospital building includes medical facilities to be assigned to medical and dental practitioners who are shareholders of the Company.

### Competition and Business Analysis

The Company belongs to the industry which caters to the need of the public and medical specialist for hospital facilities. The geographic area of competition is within Cebu City and over the five (5) kilometer radius to the north and the south where the following hospitals are operating:

HOSPITAL	LOCATION	BED CAPACITY	CATEGORY	LEVEL CLASSIFICATION
St Anthony Mother & Child Hospital	Mambaling	25	Public	Level I
Adventist Hospital	San Nicolas	100	Private	Level II
St. Vincent General Hospital	Sambag I	100	Private	Level II
Sacred Heart Hospital	Sambag II	150	Private	Level II
Chong Hua Hospital	Capitol	660	Private	Level III
Cebu Doctors' University Hospital	Capitol	300	Private	Level III
Talisay District Hospital	Talisay	250	Public	Level II
Vicente Sotto Memorial Medical Center	Sambag II	1,200	Public	Level III
Cebu Velez General Hospital	Cogon - Ramos	200	Private	Level III
Visayas Community Medical Center	Cogon - Ramos	200	Private	Level III

The Company's bigger competitors are located in the north of Cebu City; on the other hand, the Company's hospital is located in the southern part where it will be directly competing with only the smaller hospitals. The reasonable price, quality of medical care and facilities of the Company will be its edge over its competitors.

The principal suppliers of the Corporation are the following:

1. Siemens AG – CT-Scan
2. Shimadzu – X-Ray
3. General Electric Company – Mammogram



4. Mitsubishi – Elevators
5. FEPA Engineering – Air Conditioners
6. Zafire Distributors Inc – Clinical Laboratory equipment
7. Health Solutions Enterprises Inc – Ultrasound Machines, Operating Room Lights
8. MedRec Inc - Auxillary System, network switches, PABX
9. Phelps Dodge Philippines Energy Products Corporation – Electrical wires
10. Steel Asia Manufacturing Corporation – Steel Bars

The Company is not expected to be dependent upon one or a limited number of suppliers for its hospital equipment.

#### Government Regulation

ACE Medical Center - Cebu, Inc. has secured the necessary permits to construct the Hospital. Other permits acquired are from the local government unit.

In the course of its pre-operation stage, ACE Medical Center – Cebu, Inc. will secure permits and licenses from national and local government entities particularly the License to Operate (LTO) from the Department of Health (DOH), and Hazardous Waste Permit from Department of Environment and Natural Resources (DENR). The Building Permit and Occupancy Permit has been issued by the Cebu City Office of the Building Official and Business Permit from BPLO of Cebu City on July 17, 2020.

The License to Operate (LTO) will be secured after the full construction of the Hospital and the necessary Occupancy Permit from the Building Official has been issued. The Department of Health (DOH) will need to conduct ocular inspection of the facilities of the Hospital, as well as the pre-operation procedures of ACE Medical Center - Cebu, to ensure it is compliant with the standards of the Department prior to issuance of the LTO. Currently, it has secured a license from the Food and Drug Administration expiring on November 2020.

The Company has secured the required Environmental Compliance Certificate (ECC) from the DENR.

## Total Number of Employees

### **Total Number of Full Time-Employees (As of December 31, 2019):**

	<b>CBA</b>	<b>Non-CBA</b>	<b>Total</b>
Rank and File	-	5	5
Supervisors	-	4	4
Managers and Top Management	-	0	0
<b>Total</b>	<b>-</b>	<b>9</b>	<b>9</b>

It is expected that the hiring of personnel will increase for the ensuing year as soon as the hospital commences its operation.

## **C. Securities of the Registrant**

### **Market Price, Dividend and Related Stockholder Matters**

The Company's common equity are sold through its own internal staff. The shares are sold in tranches for easier administration and on a first-come, first-served basis, subject to pre-qualification procedures.

The price as of March 20, 2020 (latest practicable trading date) is P300,000.00.

#### **(1) Holders**

There are 1,702 holders of common shares and 54 holders of founder shares of the Company as of 30 June 2020.

There are no recent sales of unregistered or exempt securities including recent issuance of securities constituting an exempt transaction.

Please refer to Annex “C” page 47 for the list of top 20 stockholders as of June 30, 2020.

No dividends were declared in 2017, 2018 and 2019.

There are no restrictions that limit the payment of dividends on Common Shares.

There is no recent sale of unregistered or exempt securities.

#### **D. Management’s Discussion and Analysis or Plan of Operation**

##### **Management’s Discussion and Analysis**

The Company is set to start operation in August 2020. The working capital will be sourced from the Land Bank of the Philippines in the amount of PHP 50,000,000.00 and Development Bank Corporation in the amount of PHP 70,000,000.00. Anytime, the company can drawdown from these standby credit facilities in the event the company will already need them. The Company is also using the proceeds from the Company’s sale of its shares for the completion of the hospital facility and soon for cost of operations.

During the start of its operation, the hospital will operate as a Level 1 hospital, as recommended and approved by the Department of Health.

As a start up hospital, its revenue will be generated from Laboratory, Radiology, Pharmacy, diagnostic procedures, canteen, Central Supply Resources, Operating Room, Delivery Room, In-patients, Out-patients and clinic rentals. After three months, the hospital will apply for a Level II Accreditation and will offer additional line of services as allowed as allowed in the Level II Category.

For the next twelve months, the hospital will expand its services. Specialty Centers will be put up like ICU, NICU Isolation, PICU, Maxillo-facial Center, Rehabilitation Department, Eye Center, Hearing Center, Diabetes Center. The Cath Lab and MRI sections which are already in place are future projects in 2021 to 2022

The projected shortage of nurses is to last for the next two years. The number of beds will be dependent on the number of nurses available.

The Board has approved the purchase of fifteen hemodialysis machines in the next twelve months.

The corporation is expected to hire additional employees but will be dependent on its bed capacity.

The operations will be based on the organizational structure. The governing body is the Board of Directors with the President as chief operating officer. The chairman presides during board meetings and gives direction to the body. Under the CEO are three main divisions which are the administrative, medical and finance. A chief financial officer will be hired. Monthly meetings will take up census reports and concerns of the different departments wherein immediate solutions are implemented. Major decisions are elevated to the Board for final approval. Procurement will pass thru strict guidelines to ensure fair and honest bidding and awarding. The internal auditor will conduct quarterly monitoring and reports directly to the president.

For efficiency operations, the Bizbox Hospital Information and Accounting System has been engaged.

The following table shows the financial highlights of the Company for the quarter ended March 31, 2020 and December 31, 2019, :

	<b><i>March 31, 2020</i></b>	<b><i>Dec. 31, 2019</i></b>	<b><i>Dec. 31, 2018</i></b>
<b>Income Statement Data</b>			
Total Revenues	0	0	0
Gross Profit			
Operating Income	0	0	0
Net Income (Loss) *	(4,202,143)	(24,629,712)	(14,852,294)
<b>Total Resources</b>	<b>1,246,712,210</b>	<b>1,274,941,249</b>	<b>1,005,121,417</b>

KEY PERFORMANCE INDICATORS	March31 2020	Dec. 31, 2019	Dec. 31, 2018
<b>1. Liquidity</b> <b>a. Quick ratio</b> - capacity to cover its short-term obligations using only its most liquid assets. [(cash + cash equiv. + A/R) / current liabilities]  <ul style="list-style-type: none"> <li>– Forecasted ratio</li> <li>– Remarks: The quick ratio for the period is higher than forecast due to higher quick assets.</li> </ul>	.67:1	.90:1	2.52:1
<b>b. Current ratio</b> - capacity to meet current obligations out of its liquid assets. (current assets / current liabilities)  <ul style="list-style-type: none"> <li>– Forecasted ratio</li> <li>– Remarks: The current ratio for the period is higher than forecast due to higher quick assets.</li> </ul>	.67:1	1.36:1	4.77:1
<b>2. Solvency</b> <b>a. Debt to equity ratio</b> - indicator of which group has the greater representation in the assets of the Company. (long-term debt / equity)  <ul style="list-style-type: none"> <li>– Forecasted ratio</li> <li>– Remarks: There is no exposure to long term debt.</li> </ul>	1.73:1	1.77:1	1.23:1
	March31 2020	Dec. 31, 2019	Dec. 31, 2018
<b>2. Profitability</b>			

<p><b>a. Net profit margin</b> - ability to generate surplus for stockholder</p> <p>(net income / sales)</p> <ul style="list-style-type: none"> <li>– Forecasted ratio</li> <li>– Remarks: The Company's Net Profit Margin target was met.</li> </ul>	N/A	N/A	N/A
<p><b>b. Return on equity</b> - ability to generate returns on investment of stockholders.</p> <p>(net income / stockholders equity)</p> <ul style="list-style-type: none"> <li>– Forecasted ratio</li> <li>– Remarks: The Company's Return on Equity forecast was achieved.</li> </ul>	N/A	N/A	N/A
<p><b>3. Leverage</b></p> <p><b>b. Debt to total asset ratio</b> - the proportion of total assets financed by creditors.</p> <p>(total debt / total assets)</p> <ul style="list-style-type: none"> <li>– Forecasted ratio</li> <li>– Remarks: Debt to asset ratio was met due to higher total assets than forecast.</li> </ul> <p><b>c. Asset to equity ratio</b> - indicator of the overall financial stability of the Company.</p> <p>(total assets / equity)</p> <ul style="list-style-type: none"> <li>– Forecasted ratio</li> <li>– Remarks: The Company is financially stable and is capable of internally financing its obligations.</li> </ul>	.64:1  2.77:1	.64:1  2.77:1	.55:1  2.24:1
<p><b>4. Interest Rate Coverage Ratio</b></p> <p><b>a. Interest rate coverage ratio</b> - measure of the company's ability to meet its interest payments</p>	N/A	N/A	N/A

	(earnings before interest and taxes / interest expense)			
-	Forecasted ratio			
-	Remarks: The Company has no exposure to long-term debt.			

## PART I--FINANCIAL INFORMATION

### Item 1. Financial Statements.

The unaudited interim financial statements which comprise the unaudited statement of financial position as of March 31, 2020 and the unaudited statements of comprehensive income, cash flows and changes in stockholders' equity for the quarter ended March 31, 2020 are filed herein as part of this Form 17-Q under the following exhibits:

Exhibit 1: Unaudited Statement of Financial Position as of March 31, 2020 and Audited Statement of Financial Position as of December 31, 2019.

Exhibit 2: Unaudited Statement of Comprehensive Income for the quarters ended March 31 and March 31, 2020

Exhibit 3: Unaudited Statement of Cashflows for the quarter ended March 31, 2020.

Exhibit 4: Unaudited Statement of Changes in Stockholders' Equity for the quarter ended March 31, 2020.

Exhibit 5: Notes to Unaudited Financial Statements.

The financial statements have been prepared in accordance with the Philippine Financial Reporting Standards (PFRS). No other material subsequent event to the end of this interim period that had not been reflected in the unaudited financial statements.

### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

#### A. Financial Condition

##### 2020 vs. 2019

**Current Assets.** Cash and cash equivalent decreased by 38.7M due to the ongoing construction of the hospital facility. Subscription receivables decreased by P10.9M due to payments of shares subscribed. Prepayments and Other current assets decreased by P0.4M due to delivery of medical equipment previously paid in advance already delivered and becomes part of the Fixed Assets.

Increase in the value of Property, plant and equipment is primarily due to additional costs incurred for the ongoing construction of the hospital facility during the year.

**Current Liabilities.** Accounts Payable was decreased by 6.4M mainly due to the medical equipment purchased. Income Tax Payable of P2,073 represents the minimum corporate income tax due from sale of scrap amounting P85,000. Increase in Current portion of long term debt is decreased by 4.5M due to payment of principal loan. Due to Contractors is decreased by 13.3M due to partial payment of retention payable and architect fee for the building plan.

**Long-term Debt.** Long term debt remains at 665.56M as of March 31, 2020. Net increase of the Deferred

Tax Assets is due to the additional net operating loss carry-over during the period. Advances from Stockholders/Founders- was fully paid as of December 31, 2019.

#### **2019 vs. 2018**

Current Assets. Cash and cash equivalent decreased by 3.8M due to the ongoing construction of the hospital facility. Subscription receivables increased by P16.2M due to additional stock subscription not yet fully paid. Prepayments and Other current assets decreased by P37.9M due to equipment previously paid in advance already delivered and becomes part of the Fixed Assets.

Increase in the value of Property, plant and equipment is primarily due to on going construction of the hospital facility during the year.

Current Liabilities. Accounts Payable was increased by 55.4M mainly due to equipment purchased not fully paid. Income Tax Payable of P2,073 represents the minimum corporate income tax due from sale of scrap amounting P85,000. Increase in Current portion of long term debt is increased by 22.2M represents the amount due to the bank during the next 12 month period. Due to Contractors is increased by 23.6M the amount of retention payable and architect fee for the building plan..

Long-term Debt. Long term debt was increased by 167.54M due to additional drawdown from the credit line from LBP to finance the on going construction of hospital facility. Net increase of the Deferred Tax Assets is due to the additional net operating loss carry-over during the period. Advances from Stockholders/Founders- is decreased by 9.5M due the payment made by the corporation to its related parties.

#### **2018 vs. 2017**

Current Assets. Cash and cash equivalent increased by 52.1M due to loan drawdown from Landbank of the Philippines. Subscription receivables have been increased to 5.9M as December 31, 2018 from zero recorded at the beginning of the year. Prepayments and Other current assets decreased by P20.6M representing advance payments of the future purchases of equipment and services from contractors..

Increase in the value of Property, plant and equipment amounting to 214.9M primarily due to on going construction of the hospital facility during the year.

Current Liabilities. Accounts Payable was decreased by 17.1M mainly due to payments of accounts due during the year. Current portion of long term debt is increased by 4.5M represents the amount due to the bank during the next 12 month period. Due to Contractors is increased by 4.4M the amount attributable to retention payable and architect fee for the building plan..

Long-term Debt. Long term debt was increased by 254.1M due to additional drawdown from the credit line from LBP to finance the on going construction of hospital facility. Net increase of the Deferred Tax Assets is increased 6.2M due to the additional net operating loss carry-over during the year 2018.

**The following table shows the financial highlights of the Company for the quarter ended March 31, 2020, 2019 and 2018.**

	<i>March 31, 2020</i>	<i>March 31, 2019</i>	<i>March 31, 2018</i>



<b>Income Statement Data</b>			
Total Revenues	0	0	0
Gross Profit			
Operating Income	0	0	0
Net Income (Loss)	(4,202,143)	(3,602,250)	(3,713,074)
<b>Total Resources</b>	<b>1,246,712,210</b>	1,274,941,249	1,005,121,417

<b>KEY PERFORMANCE INDICATORS</b>	<b>March 31 2020</b>	<b>Dec. 31, 2019</b>	<b>Dec. 31, 2018</b>
<b>1. Liquidity</b>  <b>a. Quick ratio</b> -capacity to cover its short-term obligations using only its most liquid assets. [(cash + cash equiv. + A/R) / current liabilities]	.67:1	.90:1	2.52:1
<b>b. Current ratio</b> - capacity to meet current obligations out of its liquid assets. (current assets / current liabilities)	.67:1	1.36:1	4.77:1
<b>2. Solvency</b>  <b>a. Debt to equity ratio</b> - indicator of which group has the greater representation in the assets of the Company.	1.73:1	1.77:1	1.23:1
<b>2. Profitability</b> <b>a. Net profit margin</b> - ability to generate surplus for stockholder  (net income / sales)	See remarks	See remarks	See remarks
Remarks: The profitability ratio can only be computed once the hospital is operational			

<b>b. Return on equity</b> -ability to generate returns on investment of stockholders.  (net income / stockholders equity)   Remarks: As of this reporting date, the ROE can't be Computed as the entity is not yet operational.	See remarks	See remarks	See remarks
<b>3. Leverage</b> <b>b. Debt to total asset ratio</b> - the proportion of total assets financed by creditors. (total debt / total assets)  <b>c. Asset to equity ratio</b> - indicator of the overall financial stability of the Company.  (total assets / equity)	.64:1  2.77:1	.64:1  2.77:1	.55:1  2.24:1
<b>4. Interest Rate Coverage Ratio</b> (earnings before interest and taxes / interest expense)  Remarks: No earnings yet, therefore this ratio is not applicable	See remarks	See remarks	See remarks

#### Basic Loss per Share:

This represent the total loss per share because of the operations of the Company. It is computed as total loss for the quarter divided by the outstanding shares as of the period then ended. As of the quarter ended March 31, 2020, total loss per share is equivalent to Php25.07.

#### B. Known Trends, Demands, Commitments, Events or Uncertainties

There are no known demands, commitments, events or uncertainties that will have a material impact on the Bank's liquidity within the next twelve (12) months.

#### C. Events that will trigger direct or contingent financial obligation

There are no known events that will trigger the Company to incur any direct or contingent financial obligation as of the period then ended.

#### D. Material Off-Balance sheet transactions, arrangements or obligations.

As disclosed in Note 10 in the Notes to the Financial Statements, pursuant to the credit line availed by the Company from a reputable

local bank, the company has mortgaged a real estate covering the Company's land including all other existing and future improvements thereon. Stated also in the loan agreement that a grace period of three (3) years has been granted by the Bank for the payment of its principal amounts. Further, the loan agreement also provided certain restriction and requirement which include, among others, the maintenance of financial ratios (current ratio at 1:1 and debt-to-equity ratio of 80:20), the percentage of ownership of specific shareholders and the creation of property encumbrances and the additional guarantees for the incurrence of additional long-term indebtedness.

After drawing down all of the standby credit from the Land bank of the Philippines to finance the construction of the hospital facility the company is planning of repackaging the outstanding debts from 10 years to 20 years to match the depreciation period of the building and payment terms and with that the company will be able to maintain the financial ratios set forth by the creditor.

#### E.Capital Expenditures

The Company has paid purchased hospital linens, hospital equipment and other fixed assets from various suppliers that are yet to be delivered later part of this year. This is lodged under 'Advances to Suppliers'. As at the month ended March 31, 2020, the total Advances to Suppliers amounted to P24.4M

Further, construction-in-progress increased to 859,850,519 as at March 31, 2020 and the increase was attributed to additional constructions costs and capitalized borrowing costs amounting to Php13.79million and Php10.69million, respectively.

As disclosed in Note 8 in the Notes to Financial Statements, the percentage of completion of the construction of its building and medical facility is estimated at 97% as of March 31, 2020. It is expected that commercial operation will start later this year.

#### F. Significant Elements of Income or Loss

The Company has not yet started its commercial operations. Income earned from interest on bank deposits and other income net of unrealized foreign exchange loss amounted to Php533,821 for the nine months ended March 31, 2020. Also, general and administrative expenses for the same period ended amounted to Php4.74 millions

As of ended March 31, 2020, the current ratio of the Company decreased to 1.23:1 from 1.36:1 ratio as of December 31, 2019.

#### Basic Loss per Share:

This represent the total loss per share because of the operations of the Company. It is computed as total loss for the quarter divided by the outstanding shares as of the period then ended. As of the quarter ended March 31, 2020, total loss per share is equivalent to Php25.07.

#### B. Known Trends, Demands, Commitments, Events or Uncertainties

There are no known demands, commitments, events or uncertainties that will have a material impact on the Bank's liquidity within the next twelve (12) months.

#### C. Events that will trigger direct or contingent financial obligation

There are no known events that will trigger the Company to incur any direct or contingent financial obligation as of the period then ended.

#### D. Material Off-Balance sheet transactions, arrangements or obligations.

As disclosed in Note 10 in the Notes to the Financial Statements, pursuant to the credit line availed by the Company from a reputable local bank, the company has mortgaged a real estate covering the Company's land including all other existing and future improvements thereon. Stated also in the loan agreement that a grace period of three (3) years has been granted by the Bank for the payment of its principal amounts. Further, the loan agreement also provided certain restriction and requirement which include, among others, the maintenance of financial ratios (current ratio at 1:1 and debt-to-equity ratio of 80:20), the percentage of ownership of specific shareholders and the creation of property encumbrances and the additional guarantees for the incurrence of additional long-term indebtedness.

#### E. Capital Expenditures

The Company has paid purchased hospital linens, hospital equipment and other fixed assets from various suppliers that are yet to be delivered later part of this year. This is lodged under 'Advances to suppliers'. As at the month ended March 31, 2020, the total Advances to Suppliers amounted to P24.4M

Further, construction-in-progress increased to 859,850,519 as at March 31, 2020 and the increase was attributed to additional constructions costs and capitalized borrowing costs amounting to Php13.79million and Php10.69million, respectively.

As disclosed in Note 8 in the Notes to Financial Statements, the percentage of completion of the construction of its building and medical facility is estimated at 97% as of March 31, 2020. It is expected that commercial operation will start later this year.

F. Significant Elements of Income or Loss

The Company has not yet started its commercial operations. Income earned from interest on bank deposits and other income net of unrealized foreign exchange loss amounted to Php533,821 for the nine months ended March 31, 2020. Also, general and administrative expenses for the same period ended amounted to Php4.74 million.

The following table shows the financial highlights of the Company for the years then ended December 31, 2019, and 2018:

	<i>As of December 31</i>		
	<b>2019</b>	<b>2018</b>	<b>2017</b>
<b>Income Statement Data</b>			
Total Revenues	0	0	0
Gross Profit			
Operating Income	0	0	0
Net Income (Loss) *	(24,629,712)	(14,852,294)	(19,679,949 )
<b>Total Resources</b>	<b>1,274,941,249</b>	1,005,121,417	705,484,121

KEY PERFORMANCE INDICATORS	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
<b>1. Liquidity</b> <b>a. Quick ratio</b> - capacity to cover its short-term obligations using only its most liquid assets. $[(\text{cash} + \text{cash equiv.} + \text{A/R}) / \text{current liabilities}]$ <ul style="list-style-type: none"> <li>Forecasted ratio</li> <li>Remarks: The quick ratio for the period is higher than forecast due to higher quick assets.</li> </ul>	.90:1	2.52:1	1.12:1
<b>b. Current ratio</b> - capacity to meet current obligations out of its liquid assets. $(\text{current assets} / \text{current liabilities})$ <ul style="list-style-type: none"> <li>Forecasted ratio</li> <li>Remarks: The current ratio for the period is higher than forecast due to higher quick assets.</li> </ul>	1.36:1	4.77:1	2.68:1
<b>2. Solvency</b> <b>a. Debt to equity ratio</b> - indicator of which group has the greater representation in the assets of the Company. $(\text{long-term debt} / \text{equity})$ <ul style="list-style-type: none"> <li>Forecasted ratio</li> <li>Remarks: There is no exposure to long term debt.</li> </ul>	1.77:1	1.23:1	4.59:1
	<b>Dec. 31, 2019</b>	<b>Dec. 31, 2018</b>	<b>Dec. 31, 2017</b>
<b>2. Profitability</b>			



(earnings before interest and taxes / interest expense)			
<ul style="list-style-type: none"> <li>- Forecasted ratio</li> <li>- Remarks: The Company has no exposure to long-term debt.</li> </ul>			

## **MATERIAL CHANGES IN FINANCIAL CONDITION**

Revenues in 2019 – During the 2019 the Company has not commenced operation

In 2018, the Company was still in construction stage and did not generate any revenue as such.

Material changes on line items in the financial statements are included in “Management’s Discussion and Analysis” below (refer to pages 36-nward).



<i>From January 1, 2019 to December 31, 2019</i>	<i>From January 1, 2018 to December 31, 2018</i>	<i>From January 1, 2017 to December 31, 2017</i>
<b>a. Cash and cash equivalents decreased by 3.8M</b>  Due to the construction in progress.	<b>a. Cash and cash equivalents increased by P52.1M</b>  due mainly to drawdown loan from LBP.to finance construction of hospital facility	<b>a. Cash and cash equivalents increased by P52.1M</b>  due mainly to drawdown loan from LBP.to finance construction of hospital facility
<b>b. Subscription Receivable</b>  Is increased by 16.2M to account for all unpaid subscribed capital	<b>b. Subscription Receivable</b> Is increased by 5.9M for all unpaid subscribed capital stock	<b>b. Subscription Receivable</b> Is increased by 5.9M for all unpaid subscribed capital stock
<b>c. Prepayments and Other Current Assets is decreased by 37.9M</b> due to delivery of Medical equipment previously paid in advance	<b>c. Prepayments and other current assets is increased by P20.6M</b> mainly due to advances made for equipment ordered for future delivery .	<b>c. Prepayments and other current assets is increased by P20.6M</b> mainly due to advances made for equipment ordered for future delivery .
<b>d. Property, plant and equipment Is increased by P288.1M</b> primarily due to the addition of construction in progress during the year and the capitalization of the borrowing costs.	<b>d. Property, plant and equipment increased by P214.9M</b> primarily due to the addition of construction in progress during the year and the capitalization of the borrowing costs.	<b>d. Property, plant and equipment increased by P214.9M</b> primarily due to the addition of construction in progress during the year and the capitalization of the borrowing costs.
<b>e. Deferred Tax Assets increased by P7.2M</b> representing NOLCO	<b>e. Deferred Tax Assets increased by P6.2M</b> representing NOLCO	<b>e. Deferred Tax Assets increased by P6.2M</b> representing NOLCO

<i>From January 1, 2019 to December 31, 2019</i>	<i>From January 1, 2018 to December 31, 2018</i>	<i>From January 1, 2017 to December 31, 2017</i>
<b>f. Accounts Payable and OCL increased by P55.4M</b> due to balance payable on Medical Equipment purchased	<b>f. Accounts Payable and OCL increased by P17.1M</b> due to balance payable on Medical Equipment purchased	<b>f. Accounts Payable and OCL increased by P17.1M</b> due to balance payable on Medical Equipment purchased
<b>g. Current-portion of LTD Increased by P22.2M</b> due to maturity of portion of loans payable to LBP.	<b>g. Current-portion of LTD Increased by P4.5M</b> due to maturity of portion of loans payable to LBP.	<b>g. Current-portion of LTD None</b> due to no maturity of portion of loans payable to LBP.
<b>h. Due to Contractors increased by 23.6M</b> due to the retention payable and professional fees due to architect	<b>h. Due to Contractors increased by 4.4M</b> due to the retention payable and professional fees due to architect	<b>h. Due to Contractors increased by</b>  due to the retention payable and professional fees
<b>i. Long-term Debt is increased by P167.54M</b> due to the ongoing construction of the hospital facility as part of PPE.	<b>i. Long-term Debt is increased by P254.1M</b> due to the ongoing construction of the hospital facility as part of PPE.	<b>i. Long-term Debt is increased</b>  due to the ongoing construction of the hospital facility as part of PPE.
<b>j. Advances from Stockholders Is decreased by 9.5M</b> This accounts have been fully paid by the corporation as at December 31, 2019.	<b>j. Advances from Stockholders Is increased by 8.3M</b> This accounts represents loan from founders during the year.	<b>j. Advances from Stockholders Is increased by 1.5M</b> This accounts represents loan from stockholders.
<b>k. Deposit for future Stock Subscription</b> This account has been 0 during the year.	<b>k. Deposit for future Stock Subscription decreased by 277.7M</b> This account has been derecognized during the year.	<b>k. Deposit for future Stock Subscription</b> This account represents the cash deposited to the corporation prior to the secondary license from SEC

## KEY PERFORMANCE INDICATORS

(Note: Allied Care Experts (ACE) Medical Center Inc.)

		Dec. 31 2019	Dec. 31 2018	Dec. 31 2017
<b>A. Liquidity</b>				
<b>1. Quick ratio -</b>	capacity to cover its short-term obligations using only its more liquid assets. [(cash + cash equiv. + A/R) / current liabilities]	.90:1	2.52:1	1.12:1
	- Forecasted ratio	3.54:1	3.60:1	1.74:1
	Remarks: The quick ratio for the period is higher than forecast due to lower loans and trade payables in 2019. Funds derived from collection of receivables were used to settle the Company's liabilities.			
<b>2. Current ratio -</b>	capacity to meet current obligations out of its liquid assets.  (current assets / current liabilities)	.90:1	2.52:1	1.12:1
	- Forecasted ratio	6.33:1	6.03:1	2.82:1
	Remarks: The Company's Current ratio is lower than forecast due to lower loans and trade payables in 2019. Funds derived from collection of receivables were used to settle the Company's liabilities.			
<b>B. Profitability</b>				
<b>3. Net profit margin</b>	- ability to generate surplus for stockholders. (net income / sales)	NA	NA	NA
	- Forecasted ratio	5%	4%	4%
	Remarks: The Company's Net Profit Margin target was not met.			
<b>4. Return on equity -</b>	ability to generate returns on investment of to generate returns on investment of stockholders  (net income / stockholders equity)	NA	NA	NA
	- Forecasted ratio	5%	5%	5%
	Remarks: The Company's Return on Equity forecast was not met.			

	Dec. 31 2019	Dec. 31 2018	Dec. 31 2017
<b>C. Leverage</b>			
<b>5. Debt to total asset ratio -</b> the proportion of total assets financed by creditors (total debt / total assets)  - Forecasted ratio  Remarks: Debt to asset ratio was met. Improvement of the debt to asset ratio is attributable to the lower level of liabilities in 2019.	0.64:1  0.10:1	0.55:1  0.10:1	.82:1  0.25:1
<b>6. Debt to equity ratio -</b> an indicator of which group has the greater representation in the assets of the Company (long-term debt / equity)  - Forecasted ratio  Remarks: There is an exposure to long term debt.	1.77:1  0.02:1	1.24:1  0.02:1	4.59:1  0.09:1

As disclosed in the Notes to the Financial Statements (page 21 of the 2019 AFS), on September 1, 2016 the Company applied for a credit line from [Landbank ], for which the company has mortgaged its land situated in 982 Bacalso Ave., Basak, Pardo, Cebu City, including all other existing and future improvements thereon. The loan amounts to P465 million payable in ten years and P35 million payable in seven years for the construction expense including elevators and generators. On August 24, 2018, an equipment loan worth P350 million was granted payable in seven years. Annual interest is six percent. Among the salient terms of the loan agreement are as follows: (1) a grace period of three (3) years has been granted by the Bank for the payment of its principal amounts; (2) certain restriction and requirement were imposed, which include, among others, the maintenance of financial ratios (current ratio at 1:1 and debt-to-equity ratio of 80:20); (3) the percentage of ownership of specific shareholders; (4) creation of property encumbrances; and (5) additional guarantees for the incurrence of additional long-term indebtedness

There are no events that will trigger direct or contingent financial obligation that is material to the Company, including any default or acceleration of an obligation.

There are no material off-balance sheet transactions, arrangements, obligations (including contingent obligations) and other relationships of the company with unconsolidated entities or other persons created during the reporting period.

#### *Financial Risks*

- a. Interest Rate Risk – The Company's interest rate risk is limited to its trust receipts and short-term loans.

- b. Foreign Currency Risk – Exposure to said risk arises from deposits and placements and importation of finished goods, raw materials and equipment in foreign currency. Purchases of finished goods and raw materials are subject to an open account with foreign suppliers and are settled within a month from arrival or through a peso trust receipts financing from a local bank as soon as documentation requirements are completed.
- c. Credit Risk – The Company has a policy to require customers who wish to buy on credit terms to comply and undergo a credit verification process concentrating on capacity, character and willingness to pay. Receivables are closely monitored to ensure that changes in credit quality are recognized and exposure to bad debts is minimized.
- d.** Liquidity Risk – The Company maintains a balance between continuity of funding and flexibility using bank loans and purchase contracts. The Company has no investments in foreign securities.

## **2019 COMPARED TO 2018**

**Current Assets. Cash and cash equivalent** decreased by 3.8M payment of advances from Founders/Stockholders. Subscription **receivables** increased by P16.2M due to additional stock subscription not yet fully paid. Prepayments and **Other current assets** decreased by P37.9M due to equipment previously paid in advance already delivered and becomes part of the Fixed Assets.

Increase in the value of **Property, plant and equipment** is primarily due to on going construction of the hospital facility during the year.

Increase in **Investment properties of a subsidiary** represents additional capitalized cost relating to a previous acquisition.

Net increase of the **Deferred Tax Assets** is due to the additional net operating loss carry-over.

**Current Liabilities. Accounts Payable** was increased by 55.4M mainly due to equipment purchased not fully paid. **Income Tax Payable** of P2,073 represents the minimum corporate income tax due from sale of scrap amounting P85,000. **Increase in Current portion of long term debt** is increased by 22.2M represents the amount due to the bank during the next 12 month period. **Due to Contractors** is increased by 23.6M the amount of retention payable and architect fee for the building plan..

**Long-term Debt.** Long term debt was increased by 167.54M due to additional drawdown from the credit line from LBP to finance the on going construction of hospital facility.

**Advances from Stockholders/Founders-** is decreased by 9.5M due the payment made by the corporation to its related parties.

### **Changes in Operating Results**

The company is about to start operation and there is no disclosure as to revenue except that preoperating expenses accounted for and audited by Minerva and Company CPAs'

The Net Loss is increased substantially due to the finance costs incurred during the year as shown in the statement of comprehensive and Notes to Financial Statements.

Net loss from operation in 2018 of Php 14.8 Million increased by 69 % to Php 25.1 Million in 2019 as the company still has not operated its business and will open on August 2020.

While it has managed to keep its general and administrative expenses down slightly from Php 21.6 Million to Php 21.9 Million, it has now carried finance cost to loan of 11.4M for the completion of its building and purchase of hospital equipment from Php 775 Million to Php 1.069 Billion in 2019. The NOLCO tax benefit of Php 3.3 Million for losses available for 2019 could not be availed yet while not yet **in operation**.

## **2018 COMPARED TO 2017**

**Current Assets. Cash and cash equivalent** increased by 52.1M due to additional loan drawdown from LBP to finance construction of the hospital facility temporarily held in the bank as short term placement.. Subscription **receivables** increased by P5.9M due to additional stock subscription not yet fully paid.

**Prepayments and Other current assets** increased by P20.6M as downpayment of for the medical equipment for future delivery.

Increase in the value of **Property, plant and equipment** is primarily due to on going construction of the hospital facility during the year.

Increase in **Investment properties of a subsidiary** represents additional capitalized cost relating to a previous acquisition.

Net increase of the **Deferred Tax assets** is due to the additional net operating loss carry-over.

**Current Liabilities. Accounts Payable** was decreased by 17.1M mainly due to payment..**Increase in Current portion of long term debt** is increased by 4.5M represents the amount due to the bank during the next 12 month period. **Due to Contractors** is increased by 4.4M the amount of retention payable and architect fee for the building plan..

**Long-term Debt.** Long term debt was increased by 254.1M due to additional drawdown from the credit line from LBP to finance the on going construction of hospital facility. Unspent portion was deposited in a reputable bank as regular time deposit.

**Advances from Stockholders/Founders-** is increased by 8.3M due the loan from founders without interest for the purpose of

#### Changes in Operating Results

The company is about to start operation and there is no disclosure as to revenue except that pre-operating expenses accounted for and audited by Minerva and Company CPAs'

The Net Loss in 2018 is reduced by the interest income and income tax benefit as shown in the statement of comprehensive income and notes to Financial Statements.

Net loss in 2017 of Php 19.6 Million reduced to Php 14.8 Million in 2018 maintaining expenses at same level. With cash and cash equivalent were up from Php 63 Million to Php 115 Million in 2018 due to loans availed for the construction of the building and sale of shares of Php 5.9 Million under subscription receivable with total loans availed at Php 260 Million. Total non-current asset as of December 31, 2018 stood at Php 775 Million up 40% from Php 221 Million in 2017. Total asset stood at Php 1,005,121,417 as of December 31, 2018.

#### **2017 COMPARED TO 2016**

**Current Assets. Cash and cash equivalent** increased by 52.1M due to additional loan drawdown from LBP to finance construction of the hospital facility temporarily held in the bank as short term placement.. Subscription **receivables** increased by P5.9M due to additional stock subscription not yet fully paid. **Prepayments and Other current assets** increased by P20.6M as downpayment of for the medical equipment for future delivery.

Increase in the value of **Property, plant and equipment** is primarily due to on going construction of the hospital facility during the year.

Increase in **Investment properties of a subsidiary** represents additional capitalized cost relating to a previous acquisition.

Net increase of the **Deferred Tax assets** is due to the additional net operating loss carry-over.

**Current Liabilities. Accounts Payable** was decreased by 17.1M mainly due to payment. **Increase in Current portion of long term debt** is increased by 4.5M represents the amount due to the bank during the next 12 month period. **Due to Contractors** is increased by 4.4M the amount of retention payable and architect fee for the building plan..

**Long-term Debt.** Long term debt was increased by 254.1M due to additional drawdown from the credit line from LBP to finance the on going construction of hospital facility. Unspent portion was deposited in a reputable bank as regular time deposit.

**Advances from Stockholders/Founders-** is increased by 8.3M due the loan from founders without interest for the purpose of

#### Changes in Operating Results

The company is about to start operation and there is no disclosure as to revenue except that pre-operating expenses accounted for and audited by Aniceto M. Yu and Associates

The Net Loss in 2017 is increased substantially due the penalties imposed by the regulator, promotional expenses and salaries and allowances expenses as shown in the Notes to Financial Statements.

There are no material off-balance sheet transactions, arrangements, obligations and other relationships of the Company with unconsolidated entities or other persons created during the reporting period.

The Company continues to spend for regular capital expenditures as the construction of the hospital facility is going on.

The Company intends to commence its business operations in the last quarter of 2020 when its hospital facility will be completed and is ready for use.

The financial condition or results of operations of the Company are not affected by any seasonal change.

There are no events that will trigger direct or contingent financial obligation that is material to the Company, including any default or acceleration of an obligation.

There are no material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the company with unconsolidated entities or other persons created during the reporting period.

#### **Loan Covenant**

As disclosed in the Notes to the Financial Statements, pursuant to the credit line availed by the Company from a reputable local bank, the company has mortgaged a real estate covering the



Company's land including all other existing and future improvements thereon. Stated also in the loan agreement that a grace period of three (3) years has been granted by the Bank for the payment of its principal amounts. Further, the loan agreement also provided certain restriction and requirement which include, among others, the maintenance of financial ratios (current ratio at 1:1 and debt-to-equity ratio of 80:20), the percentage of ownership of specific shareholders and the creation of property encumbrances and the additional guarantees for the incurrence of additional long-term indebtedness.

#### *Financial Risks*

- a. Interest Rate Risk – The Company's interest rate risk is limited to its trust receipts and short-term loans.
- b. Foreign Currency Risk – Exposure to said risk arises from deposits and placements and importation of finished goods, raw materials and equipment in foreign currency. Purchases of finished goods and raw materials are subject to an open account with foreign suppliers and are settled within a month from arrival or through a peso trust receipts financing from a local bank as soon as documentation requirements are completed.
- c. Credit Risk – The Company has a policy to require customers who wish to buy on credit terms to comply and undergo a credit verification process concentrating on

capacity, character and willingness to pay. Receivables are closely monitored to ensure that changes in credit quality are recognized and exposure to bad debts is minimized.

- d. Liquidity Risk – The Company maintains a balance between continuity of funding and flexibility using bank loans and purchase contracts. Short-term loans availed for operating requirements usually mature within one year while loans through trust receipts within 180 days. Other payables usually mature within 60 days.

The Company has no investments in foreign securities.

#### **E. Certain Relationships and Related Transactions**

- (1) Except for Ms. Floram Limotlimot (Corporate Treasurer) and Ms. Joy Luna (Director) and Dr. Amado Manuel C. Enriquez, Jr. (Chairman) and Dr. Miguel Antonio R. Enriquez (Nominee), there are no other family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, persons nominated or chosen by the Company to become directors, or executive officers, any security holder of certain record, beneficial owner or management.
- (2) Aside from the party mentioned above, there is no other relationship that has existing negotiations on material transactions.
- (3) In 2019, the outstanding advances from its founders in the amount of PHP 9,503,555.00 as reflected in the 2018 Annual Financial Statement was paid off without interest by the Company.

- (4) There is no transaction with promoters for the past 5 years.

## **F. Management and Certain Security Holders**

### **Directors, Executive Officers**

There are fifteen (15) members of the Board, two (2) of whom are independent directors who hold office for one (1) year. Please refer to pages 9 to 10 for the list of incumbent directors/officers. The Corporation relies significantly on the continued collective efforts of its senior executive officers and expects each employee to do his share in achieving the Corporation's goals.

Except for Ms. Floram Limotlimot (Corporate Treasurer) and Ms. Joy Luna (Director) and Dr. Amado Manuel C. Enriquez, Jr. (Chairman) and Dr. Miguel Antonio R. Enriquez (Nominee), there are no other family relationships up to the fourth civil degree either by consanguinity or affinity among directors, executive officers, persons nominated or chosen by the Company to become directors, or executive officers, any security holder of certain record, beneficial owner or management.

The following directors/officers are involved in the following legal proceedings in their capacity as directors/officers of the Company:

1. Geanie Cerna-Lopez
2. Velma T. Chan
3. Luisito R. Co
4. Roberto M. De Leon
5. Amado Manuel C. Enriquez, Jr.
6. Floram C. Limotlimot
7. Roland Mark Gigataras
8. Joy C. Luna
9. Nicolas S. Molon
10. Felix P. Nolasco
11. Evangeline Y. Zozobrado

### **Civil Case No. R-CEB-18-00601-CV, Branch XI, Cebu City**

**(Complaint for Issuance of Certificate of Stock, Declaration of Sale in Installment as Subscription Contract, Declaration of Rights or Pre-Emption, and for Attorney's Fees) – Ferdinand Kionisala vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. De Leon, Amado Manuel C. Enriquez Jr., Floram C. Limotlimot, Roland Mark M. Gigataras, Joy A. Luna, Nicolas S. Molon, Felix P. Nolasco, Generoso M. Orillaza, Ronald L. Ramiro, Marietta T. Samoy and Evangeline Y. Zozobrado.**

Status: Plaintiff filed a Motion for Partial Summary Judgment on May 2, 2018; respondents filed

their Opposition to the Motion on May 15, 2018; the motion is still pending at the RTC, Branch XI of Cebu City.

**Civil Case No. R-CEB-18-01248-CV, Branch XI, Cebu City**

**(Declaration of Sale in Installment as Subscription Contract, Declaration of Rights of Pre-Emption, and Attorney's Fees)** - Dax Matthew M. Quijano, Rose Marie P. Quijano, Eric Y. Cheung, Girlie Cheung and Candice Joy A. Sia vs. Geanie Cerna- Lopez, Velma T. Chan, Luisito R. Co, Maita Cruz, Roberto M. de Leon, Amado Manuel

C. Enriquez, Jr., Floram C. Limotlimot, Nicolas S. Molon, Felix P. Nolasco, Generoso

M. Orillaza, Ronald L. Ramiro, Marietta T. Samoy and Evangeline Y. Zozobrado.

Status: Respondents ACE, Velma Chan, Luisito Co, Floram Limotlimot and Mark Gigataras submitted their answer. For the Manila-based respondents, the summons were not served. The case is for still pre-trial.

**Special Civil Action Case No. R-CEB-18-08795-SC, Branch XI, Cebu City**

**(For Mandamus to Issue 100% Pre-Emptive Rights, Damages and for Attorney's Fees) - Leo T. Sumatra, Sps. Stephen Paul M. Bergado and Conchita B. Bergado, Marie Davielene Beatriz Ong-Dy and Leonard Matthew Dy, et al vs. Allied Care Experts (ACE) Medical Center-Cebu, Inc., Geanie Cerna-Lopez and Velma T. Chan**

Status: Respondents filed their Comment to the Petition last January 7, 2019; the Plaintiffs have filed their reply. Last February 2020, an Arbitration Court heard the comments of both parties. The respondents offered to buy back their shares at a higher price. Subsequent hearing has been deferred because of the Covid crisis.

**G. Corporate Governance**

The Company remains committed to its Corporate Vision-Mission.

The Corporation has filed its Manual on Corporate Governance.

The independent directors have submitted their Certificate of Qualification as required by the SEC vis-à-vis Section 38 of the Securities Regulation Code.

## ANNEX “C”

**Top 20 Stockholders**  
**Allied Care Experts (ACE) Medical Center-Cebu Inc.**  
**(As of 30 June 2020)**

6. Gigataras, Roland Mark M.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
7. Gonzalez, Julio L.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
8. Limotlimot, Floram C.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
9. Luna, Joy C.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
10. Mata, John M.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
11. Molon, Nicolas S.	Filipino	Founder – 10 Common – 2,490 Total 2,500	1.46%
12. Nolasco, Felix P.	Filipino	Founder – 10	1.46%
		Common – 2,490	
		Total – 2,500	
13. Zozobrado, Evangeline Y.	Filipino	Founder – 10	1.46%
		Common – 2,490	
		Total – 2,500	
14. Briones, Wyben R.	Filipino	Founder – 10 Common – 1,990 Total – 2,000	1.17%
15. Antigua, Neonita C.	Filipino	Founder – 10 Common – 1,190 Total – 1,200	0.70%
16. Samoy, Marietta T.	Filipino	Founder – 10	1.46%
		Common – 2,490	
		Total – 2,500	

17. Orillaza, Generoso M.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
18. Libre, Ma. Asuncion Hipolita B.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
19. Enriquez, Michael Edward R.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
20. Enriquez, Miguel R.	Filipino	Founder – 10 Common – 2,490 Total – 2,500	1.46%
<b>Total</b>		<b>63,206</b>	<b>37.06%</b>

## CERTIFICATION OF INDEPENDENT DIRECTOR

I, ESMERALDA V. DELA ROSA M.D., Filipino, of legal age and a resident of 416 Calo Street, Ayala Alabang, Muntinlupa City, having been duly sworn in accordance with law do hereby declare that:

1. I am a nominee for independent director of ACE Medical Center Cebu Inc for the year 2020-2021
2. I am affiliated with the following companies or organizations (including government-owned and controlled corporations):

Company/Organization	Position/Relationship	Period of Service
Medical Center Muntinlupa	TREASURER/ BOARD OF DIRECTORS	2017-2019
PARANAQUE DOCTORS HOSPITAL	MEDICAL DIRECTORS/ BOD	2018-2019
LAS PINAS MEDICAL CENTER INC.	<b>CHAIRMAN</b> OF THE BOARD	2017-2018

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of ACE Medical Center Cebu Inc., as provided for in Section 38 of the Securities Regulation Code, its Implementing Rules and Regulations and other SEC issuances
4. I am related to the following director/officer/substantial shareholder of UNIHEALTH PARANAQUEE other than the relationship provided under Rule 38.2.3 of the Securities Regulation Code

Name of Director/Officer/Substantial Shareholder	Company	Nature of Relationship
M R. CARLOS DELA ROSA	UNIHEALTH PARANAQUEE	HUSBAND
M R. CARLOS DELA ROSA	PARANAQUE DOCTORS HOSPITAL	HUSBAND

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding/ I disclose that I am the subject of the following criminal/administrative investigation or proceeding (as the case may be);
6. (For those in government service/affiliated with a government agency or GCC) I have the required written permission or consent from the (head of agency/department) to be an independent director in ACE Medical Center Cebu Inc. pursuant to Office f the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules



7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances

8. I shall inform the Corporate Secretary of ACE Medical Center Cebu Inc of any changes in the abovementioned information within five days from its occurrence.

Done this JUL 03 2020 day of July at ParanaQU8 City



ESMERALDA V. DELA ROSA, M.D  
Affiant

SUBSCRIBED AND SWORN to before me this \_\_\_\_ day of JUL 03 2020

$f$ 

  
ATTY. MARCUS AURELIUS M. BARARES  
Notary Public  
Commission No. 259-2020  
Unit 1 Dec. 31, 2021  
706-B Diamante St., Jacksonville Subd.  
Rof No. 58093 /

IBPNo. 09385511ori#19/Pdlig|A/  
PTR No.221480001/02/20,1'Queav  
No. VI-0019512/0712&19/Pas...ity

**CERTIFICATION OF INDEPENDENTDIRECTOR**


1. I am a nominee for independent director of Allied Care Experts (ACE} Medical Center - Cebu Inc.
2. I am affiliated with the following companies or organizations (including government-owned and controlled corporations):

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of Allied Care Experts (ACE) Medical Center - Cebu Inc., as provided for in Section 38 of the Securities Regulation Code, its Implementing Rules and Regulations and other SEC issuances

4. I am related to the following director/officer/substantial shareholder of N/A other than the relationship provided under Rule 38.2.3 of the Securities Regulation Code

Name of Director/Officer/Substantial Shareholder	Company	Nature of Relationship
<u>N/A</u>	<u>N/A</u>	<u>N/A</u>
<u>N/A</u>	<u>N/A</u>	<u>N/A</u>
<u>N/A</u>	N/A	<u>N/A</u>

5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding;
6. (For those in government service/affiliated with a government agency or GCC) I have the required written permission or consent from the (head of agency/department) to be an independent director in N/A, pursuant to Office of the President Memorandum Circular No. 17 and Section 12, Rule XVIII of the Revised Civil Service Rules



7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances

8. I shall inform the Corporate Secretary of Allied Care Experts (ACE) Medical Center Cebu Inc. of any changes in the abovementioned information within five days from its occurrence.

JUL 16 2020


Done this day of \_\_\_\_\_, at \_\_\_\_\_, Z.



RONA D L. RAMIRO  
Affiant

SUBSCRIBED AND SWORN to before me this \_\_\_\_\_ at \_\_\_\_\_  
\_\_\_\_\_ affiant personally appeared before me and exhibited to me his/her  
\_\_\_\_\_ issued on \_\_\_\_\_, at \_\_\_\_\_

Doc No *vf3*  
Page No *J'."f*  
Book No *Lill*  
Series of 2020



ANTONIO D. ARABE  
NOTARY PUBLIC - NCS NO. 2020-05  
UNTIL DECEMBER 31, 2021  
PTR NO. 0731865, 12-11-19 FOR 2021  
IBP OR NO. 094984, 11-15-19 FOR 2020  
ROLL NO. 37470, MCLE VI-0006609, 12-20-20

CERTIFICATION OF INDEPENDENT DIRECTOR

I, Felicisimo D. De Castro, Filipino, of legal age and a resident of 46CV Victoria Avenue, New Manila, Brgy. Mariana, Quezon City 1112, having been duly sworn in accordance with lawdo hereby declare that:

1. I ama nominee for independent director of ACEMC-Cebu and have been its independent director since 2019.
2. I am affiliated with the following companies or organizations (including government-owned and controlled corporations):

Company/Organization	Position/Relationship	Period of Service
Allied CareExperts <b>MedicalCenter(ACEMC)</b> - Baypointe	Current President/ Member of Board	2017-2020/2007 to present
<b>ACEMC-Valenzuela</b>	Member, Board of Directors	2017-Present
<b>ACEMC-Pateros</b>	-do-	<b>2020</b>
ACEMC-Dumaguete	-do-	<b>2020</b>
<b>ACEMC-Bohol</b>	-do-	<b>2019</b>
<b>ACEMC-Quezon City</b>	Founder Stockholder	
<b>ACEMC-Baliwag</b>	-do-	
<b>ACEMC-Tacloban</b>	-do-	
Philippine Medical Association	Life Member	
Philippine Academy of Ophthalmology	Life Member	
Olongapo CityMedical Society	Member	
<b>ACEMC-Cagayan de Oro</b>	Founder Stockholder	
<b>ACEMC-Bayawan</b>	-do-	
ACEMC-General Santos	-do-	
<b>ACEMC-Butuan</b>	-do-	
<b>ACEMC-Palawan</b>	-do-	
ACEMC-Tuguegarao	-do-	
<b>ACEMC-Malolos</b>	-do-	

3. I possess all the qualifications and none of the disqualifications to serve as an Independent Director of ACEMC-CEBU, as provided for in Section 38 of the Securities Regulation Code, its Implementing Rules and Regulations and other SEC issuances
4. I am related to the following director/officer/substantial shareholder of  
\_\_\_\_\_ other than the relationship provided under Rule 38.2.3  
\_\_\_\_\_ **MA** \_\_\_\_\_  
of the Securities Regulation Code

Name of Director/Officer/Substantial Shareholder	Company	Nature of Relationship
NA	NA	NA



- 
- 
- 
5. To the best of my knowledge, I am not the subject of any pending criminal or administrative investigation or proceeding/ I disclose that I am the subject of the following criminal/administrative investigation or proceeding (as the case may be);
6. (For those in government service/affiliated with a government agency or GCC) I have the required written permission or consent from the (head of agency/department) to be an independent director in \_\_\_\_\_ NA \_\_\_\_\_, pursuant to Office of the President Memorandum Circular No. 17 and Section 12, Rule **XVIII** of the Revised Civil Service Rules
7. I shall faithfully and diligently comply with my duties and responsibilities as independent director under the Securities Regulation Code and its Implementing Rules and Regulations, Code of Corporate Governance and other SEC issuances
8. I shall inform the Corporate Secretary of ACEMC-Ceb of any changes in the abovementioned information within five days from its occurrence.

Done this 13<sup>th</sup> day of July, 2020, at Olongapo City.

*Fμ,,*  
Felicisimo D. de Castro  
**Affiant**

SUBSCRIBED AND SWORN to before me this      day of **JUL 17 2020** at **ParafiaQue City**  
affiant personally appeared before me and exhibited to me: ✓ her NO 79-022446 issued on 2018/04/16, at De 7  
Department of Transportation Land Trans

DocNo 2.0  
PageNo Book No  
Series of 2020

Department Office.  
**ATTY. MARCUS AURELIUS M. BAÑARES**  
Notary Public  
Commission No. 259-2020  
Until 31, 2021  
706-B Dianoante St., J. Louville Subd., Bgy. F, Pque C'cy  
R No. 58093/4/31110  
IBP No 3855/10/29/19/P City  
PTR 2214890 /01/02/20 /Poue City

hC LE

pN 0. VI-0011||.1,?,"1"1"---... : ●●7",1